CoChat

An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

Published version of a preprint

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

Cell-intrinsic effects such as induction of apoptosis and/or inhibition of cell proliferation have been proposed as the major antitumor responses to histone deacetylase inhibitors (HDACi). These compounds can also mediate immune-modulatory effects that may contribute to their anticancer effects. However, HDACi can also induce anti-inflammatory, and potentially immunosuppressive, outcomes. We therefore sought to clarify the role of the immune system in mediating the efficacy of HDACi in a physiologic setting, using preclinical, syngeneic murine models of hematologic malignancies and solid tumors. We showed an intact immune system was required for the robust anticancer effects of the HDACi vorinostat and panobinostat against a colon adenocarcinoma and two aggressive models of leukemia/lymphoma. Importantly, although HDACi-treated immunocompromised mice bearing established lymphoma succumbed to disease significantly earlier than tumor bearing, HDACi-treated wild-type (WT) mice, treatment with the conventional chemotherapeutic etoposide equivalently enhanced the survival of both strains. IFN-γ and tumor cell signaling through IFN-γR were particularly important for the anticancer effects of HDACi, and vorinostat and IFN-γ acted in concert to enhance the immunogenicity of tumor cells. Furthermore, we show that a combination of vorinostat with α-galactosylceramide (α-GalCer), an IFN-γ-inducing agent, was significantly more potent against established lymphoma than vorinostat treatment alone. Intriguingly, B cells, but not natural killer cells or CD8(+) T cells, were implicated as effectors of the vorinostat antitumor immune response. Together, our data suggest HDACi are immunostimulatory during cancer treatment and that combinatorial therapeutic regimes with immunotherapies should be considered in the clinic.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-0890

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Cited by

See all 141

Metadata

Authors
West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W.
Affiliations
Translational Research Institute (AU)
Venue
Cancer Research
Published
2013-12-15
Volume
73
Issue
24
Pages
7265-7276
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2162821626
Cited by
137
References
53
Citations by year
2026: 1 · 2025: 4 · 2024: 14 · 2023: 8 · 2022: 11 · 2021: 6 · 2020: 12 · 2019: 10 · 2018: 14 · 2017: 9 · 2016: 24 · 2015: 10 · 2014: 13 · 2013: 1
FWCI
7.17
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Peter MacCallum Cancer Centre
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
histone deacetylase inhibitors, vorinostat, panobinostat, antitumor immunity, interferon-gamma, IFN-gamma receptor, immunogenic tumor cell death, alpha-galactosylceramide, B cells, lymphoma, leukemia, colon adenocarcinoma, immunosuppression, hematologic malignancies, solid tumors
MeSH terms
Interferon gamma Receptor, Adenocarcinoma, Animals, Colonic Neoplasms, Immune System, Immunotherapy, Leukemia, Lymphoid, Male, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Experimental, Apoptosis, Receptors, Interferon, Cell Line, Tumor, Cell Growth Processes, Mice, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-0890
The paper
West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2013). An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-0890

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.